ValuEngine downgraded shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) from a sell rating to a strong sell rating in a research report sent to investors on Thursday.

Other equities analysts also recently issued research reports about the company. HC Wainwright reiterated a buy rating and issued a $10.00 target price on shares of Ocular Therapeutix in a report on Wednesday, August 9th. Cantor Fitzgerald set a $35.00 target price on Ocular Therapeutix and gave the company a buy rating in a report on Monday, July 10th. Morgan Stanley downgraded Ocular Therapeutix from an overweight rating to an equal weight rating and set a $16.00 target price on the stock. in a report on Friday, June 23rd. Finally, BTIG Research reiterated a neutral rating on shares of Ocular Therapeutix in a report on Thursday, August 10th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of $22.14.

Shares of Ocular Therapeutix (OCUL) opened at 6.38 on Thursday. The company has a 50-day moving average of $6.09 and a 200-day moving average of $8.31. Ocular Therapeutix has a 12-month low of $4.82 and a 12-month high of $11.91. The stock’s market capitalization is $185.38 million.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.05). Ocular Therapeutix had a negative net margin of 3,005.52% and a negative return on equity of 101.03%. The firm had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.51 million. During the same period in the prior year, the company posted ($0.46) earnings per share. Ocular Therapeutix’s quarterly revenue was up .0% compared to the same quarter last year. Equities analysts expect that Ocular Therapeutix will post ($2.25) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “ValuEngine Lowers Ocular Therapeutix, Inc. (OCUL) to Strong Sell” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/valuengine-lowers-ocular-therapeutix-inc-ocul-to-strong-sell/1584540.html.

Several institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP increased its holdings in shares of Ocular Therapeutix by 35.2% in the 1st quarter. Wellington Management Group LLP now owns 1,312,703 shares of the biopharmaceutical company’s stock valued at $12,182,000 after purchasing an additional 341,767 shares during the period. Vanguard Group Inc. increased its holdings in shares of Ocular Therapeutix by 0.4% in the 2nd quarter. Vanguard Group Inc. now owns 905,456 shares of the biopharmaceutical company’s stock valued at $8,394,000 after purchasing an additional 3,194 shares during the period. Morgan Stanley increased its holdings in shares of Ocular Therapeutix by 84.0% in the 1st quarter. Morgan Stanley now owns 604,636 shares of the biopharmaceutical company’s stock valued at $5,611,000 after purchasing an additional 275,950 shares during the period. State Street Corp increased its holdings in shares of Ocular Therapeutix by 12.3% in the 2nd quarter. State Street Corp now owns 371,923 shares of the biopharmaceutical company’s stock valued at $3,450,000 after purchasing an additional 40,782 shares during the period. Finally, JPMorgan Chase & Co. acquired a new position in shares of Ocular Therapeutix in the 1st quarter valued at about $3,394,000. Institutional investors own 53.42% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.